WEKO3
アイテム
Carbon Ion Radiotherapy for Liver Cancer
https://repo.qst.go.jp/records/63989
https://repo.qst.go.jp/records/6398977deb270-5342-4e72-a963-2676a47e0011
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2010-09-13 | |||||
| タイトル | ||||||
| タイトル | Carbon Ion Radiotherapy for Liver Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Imada, Hiroshi
× Imada, Hiroshi× Yasuda, Shigeo× Yamada, Shigeru× Shinoto, Makoto× Oonishi, Kazuhiko× Kamada, Tadashi× Tsujii, Hirohiko× 今田 浩史× 安田 茂雄× 山田 滋× 篠藤 誠× 大西 和彦× 鎌田 正× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The objective of this paper is to present a summary of a clinical study on carbon ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) conducted from April 1995 to August 2005 at the Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, in Japan. A total of 193 patients with HCC were enrolled in the clinical trial of carbon ion beams. In the first and second phase I/II clinical trials, dose escalation experiments were carried out in incremental steps of 10%, resulting in the confirmation of both the safety and efficacy of short-course regimens of 12, 8 and 4 fractions. Based on the results, a phase II clinical study with fixed fractionation, that is, 52.8 GyE/4 fractions, was performed. A total of 47 patients were treated during this phase II study, which resulted in low toxicity and attained a high local control rate (96%) for 5 years after treatment. The last clinical study was conducted from April 2003 to August 2005 with a more hypofractionated regimen of 2 fractions/2 days, in which 36 patients were safely treated within a dose escalation range from 32.0 GyE to 38.8 GyE. The 2-fraction therapy protocol is continuing under the license of Highly Advanced Medical Technology. There have been no therapy-related deaths and no severe adverse events. We can conclude that, because of the low toxicity and high local control rate, C-ion RT has a promising potential as a new, radical, and minimally invasive therapeutic option for HCC. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | The 4th Japanese-European Joint Symposium on Ion Cancer Therapy | |||||
| 発表年月日 | ||||||
| 日付 | 2010-09-11 | |||||
| 日付タイプ | Issued | |||||
